Extracellular nanovesicles for packaging of CRISPR-Cas9 protein and sgRNA to induce therapeutic exon skipping

用于包装 CRISPR-Cas9 蛋白和 sgRNA 以诱导治疗性外显子跳跃的细胞外纳米囊泡

阅读:26
作者:Peter Gee,Mandy S Y Lung,Yuya Okuzaki,Noriko Sasakawa,Takahiro Iguchi,Yukimasa Makita,Hiroyuki Hozumi,Yasutomo Miura,Lucy F Yang,Mio Iwasaki,Xiou H Wang,Matthew A Waller,Nanako Shirai,Yasuko O Abe,Yoko Fujita,Kei Watanabe,Akihiro Kagita,Kumiko A Iwabuchi,Masahiko Yasuda,Huaigeng Xu,Takeshi Noda,Jun Komano,Hidetoshi Sakurai,Naoto Inukai,Akitsu Hotta

Abstract

Prolonged expression of the CRISPR-Cas9 nuclease and gRNA from viral vectors may cause off-target mutagenesis and immunogenicity. Thus, a transient delivery system is needed for therapeutic genome editing applications. Here, we develop an extracellular nanovesicle-based ribonucleoprotein delivery system named NanoMEDIC by utilizing two distinct homing mechanisms. Chemical induced dimerization recruits Cas9 protein into extracellular nanovesicles, and then a viral RNA packaging signal and two self-cleaving riboswitches tether and release sgRNA into nanovesicles. We demonstrate efficient genome editing in various hard-to-transfect cell types, including human induced pluripotent stem (iPS) cells, neurons, and myoblasts. NanoMEDIC also achieves over 90% exon skipping efficiencies in skeletal muscle cells derived from Duchenne muscular dystrophy (DMD) patient iPS cells. Finally, single intramuscular injection of NanoMEDIC induces permanent genomic exon skipping in a luciferase reporter mouse and in mdx mice, indicating its utility for in vivo genome editing therapy of DMD and beyond.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。